Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: London : BioMed Central, [2001-
    • الموضوع:
      Biomarkers/*metabolism ; Biomarkers, Tumor/*blood ; Carcinoma, Hepatocellular/*blood ; Carcinoma, Hepatocellular/*drug therapy ; Immune Checkpoint Inhibitors/*therapeutic use ; Immunotherapy/*methods ; Liver Neoplasms/*blood ; Liver Neoplasms/*drug therapy ; Protein Precursors/*metabolism ; Prothrombin/*metabolism ; alpha-Fetoproteins/*metabolism; Adult ; Aged ; Aged, 80 and over ; Carcinoma, Hepatocellular/genetics ; Carcinoma, Hepatocellular/pathology ; Female ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Liver Neoplasms/genetics ; Liver Neoplasms/pathology ; Male ; Middle Aged ; Prognosis ; Young Adult
    • نبذة مختصرة :
      Background: Few biomarkers can predict the efficiency of PD-1 blockade in patients with hepatocellular carcinoma (HCC). This study aimed to investigate the prognostic role of AFP and PIVKA-II in HCC patients receiving anti-PD-1 immunotherapy.
      Methods: A total of 235 HCC patients treated with PD-1 blockade were enrolled. Serum AFP and PIVKA-II levels were collected before and after treatments. The patients were divided into groups based on the reduction in AFP and PIVKA-II: AFP reduction ≤50% vs AFP reduction > 50% and PIVKA-II reduction ≤50% vs PIVKA-II reduction > 50%. The primary endpoints included objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). Binary logistic regression analyses were used to explore the related factors of ORR. A Cox proportional hazards model was employed to identify the potential prognostic factors of PFS and OS.
      Results: Among all the patients, 34.9% (82/235) achieved a complete or partial response. There was a positive correlation between AFP reduction > 50% or PIVKA-II reduction> 50% and the ORR of PD-1 blockade (P < 0.001 and = 0.003). PFS was significantly improved in patients with AFP reduction > 50% and PIVKA-II reduction > 50% (p < 0.001 and = 0.021). In addition, AFP reduction > 50% and PIVKA-II reduction> 50% were positively correlated with longer OS (p = 0.003 and 0.006).
      Conclusion: Early reductions in AFP and PIVKA-II can be predictors of the efficacy of PD-1 blockade in HCC patients.
    • References:
      Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774)
      J Vasc Interv Radiol. 2019 Aug;30(8):1194-1200.e1. (PMID: 31235408)
      Lancet. 2017 Jun 24;389(10088):2492-2502. (PMID: 28434648)
      Lancet. 2018 Mar 31;391(10127):1301-1314. (PMID: 29307467)
      Cancer Med. 2020 Jul;9(14):4962-4970. (PMID: 32419290)
      Cancers (Basel). 2019 Jun 18;11(6):. (PMID: 31216701)
      Eur J Gastroenterol Hepatol. 2013 Jun;25(6):683-9. (PMID: 23395995)
      N Engl J Med. 2020 May 14;382(20):1894-1905. (PMID: 32402160)
      J Transl Med. 2019 Mar 8;17(1):74. (PMID: 30849967)
      J Immunother Cancer. 2021 Feb;9(2):. (PMID: 33563773)
      JAMA Oncol. 2020 Nov 1;6(11):e204564. (PMID: 33001135)
      Oncotarget. 2016 Nov 22;7(47):77404-77415. (PMID: 27764805)
      Br J Cancer. 2016 Feb 2;114(3):256-61. (PMID: 26794281)
      J Thorac Oncol. 2018 Jan;13(1):97-105. (PMID: 29170120)
      J Hepatocell Carcinoma. 2021 Mar 25;8:167-176. (PMID: 33791252)
      Int J Clin Oncol. 2014 Oct;19(5):871-9. (PMID: 24218280)
      Ther Adv Med Oncol. 2021 Mar 25;13:17588359211002720. (PMID: 33854567)
      Lancet Oncol. 2018 Jul;19(7):940-952. (PMID: 29875066)
      Biomed Res Int. 2013;2013:310427. (PMID: 24455683)
      Liver Int. 2011 Mar;31(3):369-76. (PMID: 21083802)
      J Hematol Oncol. 2019 Oct 26;12(1):110. (PMID: 31655607)
      J Hepatol. 2020 Feb;72(2):307-319. (PMID: 31954494)
      JAMA Oncol. 2021 Jan 1;7(1):113-123. (PMID: 33090190)
      Annu Rev Pathol. 2011;6:425-56. (PMID: 21073339)
      CA Cancer J Clin. 2020 Jan;70(1):7-30. (PMID: 31912902)
      Liver Int. 2010 Aug;30(7):1027-32. (PMID: 20492506)
      PLoS One. 2015 May 20;10(5):e0126649. (PMID: 25992784)
      J Clin Oncol. 2015 Feb 20;33(6):550-8. (PMID: 25512453)
      Lancet. 2018 Mar 24;391(10126):1163-1173. (PMID: 29433850)
      Oncology. 2015;89(3):167-74. (PMID: 25999038)
      Liver Int. 2011 Jan;31(1):22-35. (PMID: 20874725)
      Annu Rev Pathol. 2017 Jan 24;12:153-186. (PMID: 27959632)
      Cancer. 2019 Oct 15;125(20):3603-3614. (PMID: 31251403)
      Oncology. 2019;97(2):75-81. (PMID: 31242488)
      Nat Med. 2013 Dec;19(12):1617-24. (PMID: 24216753)
      CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
    • Contributed Indexing:
      Keywords: AFP; Hepatocellular carcinoma; Immunotherapy; PIVKA-II; Survival
    • الرقم المعرف:
      0 (Biomarkers)
      0 (Biomarkers, Tumor)
      0 (Immune Checkpoint Inhibitors)
      0 (Protein Precursors)
      0 (alpha-Fetoproteins)
      53230-14-1 (acarboxyprothrombin)
      9001-26-7 (Prothrombin)
    • الموضوع:
      Date Created: 20210705 Date Completed: 20211101 Latest Revision: 20211101
    • الموضوع:
      20221213
    • الرقم المعرف:
      PMC8254996
    • الرقم المعرف:
      10.1186/s12885-021-08428-w
    • الرقم المعرف:
      34218801